Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EV-301: enfortumab vedotin versus chemotherapy in previously treated advanced urothelial cancer
2017-003344-21Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enfortumab vedotin in transitional cell carcinoma (TCC) and transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Overall survival. Started Apr 2018; status: completed.
02
Drugs
enfortumab vedotin
03
Conditions
transitional cell carcinoma (TCC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2017-003344-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003344-21.